

# Review of: "The Application and Pathway Regulation of Traditional Chinese Medicine in Lung Cancer Treatment: An Exploratory Review"

Kalok Ng<sup>1</sup>

<sup>1</sup> Asia University

Potential competing interests: No potential competing interests to declare.

This article reviews TCM's impact on key signaling pathways, aiming to clarify its mechanisms and support its clinical integration. Future research should explore TCM's potential through modern medical perspectives for enhanced lung cancer intervention.

## Comments

The paper was not well prepared. The primary issue lies in the inconsistency between the article's content and the referenced sources. Another concern is the author's practice of grouping multiple references at the end of a paragraph, rather than aligning each reference with the corresponding sentence or phrase.

For instance, while discussing the lung cancer incidence percentage, the citation's relevance to the paper's content is lacking.

References 1 to 4 do not pertain to the mortality rate. These references do not match with the phrase "the mortality rate is about 46.8 per 100,000, with the incidence showing an increasing trend year by year".

References 5 to 7 do not match with the statement 'cancer (NSCLC) is the most common histological type of lung cancer, accounting for about 85% of all lung cancer cases'

References 8 to 10 pertain to the natural product baicalin and the pharmacodynamic mechanism of RPL against lung cancer, yet these references do not align with the given statement 'The standard treatments for lung cancer include surgery, radiotherapy, chemotherapy ...'

To address these issues, the author should cite sources more meticulously by placing them alongside relevant descriptions instead of aggregating them at paragraph ends.